RKDA Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
1.4M
+31.2%
1.1M
+22.1%
901.0K
-30.8%
1.3M
-10.5%
1.5M
Cost of Revenue
812.0K
+16.0%
700.0K
-1.3%
709.0K
-19.8%
884.0K
+7.3%
824.0K
Gross Profit
631.0K
+57.8%
400.0K
+108.3%
192.0K
-54.1%
418.0K
-33.8%
631.0K
Operating Expenses
1.1M
-4.4%
1.2M
-24.8%
1.6M
-0.2%
1.6M
-76.3%
6.6M
R&D
0
0
0
0
-100.0%
9.0K
SG&A
1.1M
-4.4%
1.2M
-24.8%
1.6M
-0.2%
1.6M
-26.0%
2.1M
Operating Income
-496000
+36.3%
-779000
+43.3%
-1375000
-19.4%
-1152000
+80.8%
-5990000
EBITDA
-496000
+35.7%
-771000
+43.8%
-1373000
-19.4%
-1150000
+80.8%
-5975000
Net Income
-6266000
-42.9%
-4385000
-228.2%
-1336000
-256.1%
856.0K
+119.2%
-4458000
EPS (Basic)
$-2.09
+0.9%
$-2.11
-117.5%
$-0.97
-254.0%
$0.63
+119.3%
$-3.26
EPS (Diluted)
$-2.09
+0.9%
$-2.11
-115.3%
$-0.98
-258.1%
$0.62
+119.0%
$-3.26
Shares (Diluted)
3.0M
+43.7%
2.1M
+52.4%
1.4M
-0.3%
1.4M
+0.4%
1.4M
Arcadia Biosciences (RKDA) โ€” Financials